1-19 of 19
Marina Konopleva
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis

Naval Daver, Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi, Musa Yilmaz, Courtney D. DiNardo, Tapan M. Kadia, Mhd Yousuf Yassouf, Abhishek Maiti, Sankalp Arora, Guillermo Montalban Bravo, Guilin Tang, Gautam Borthakur, Koji Sasaki, Naveen Pemmaraju, Joie Alvarez, Graciela M. Nogueras Gonzalez, Jing Ning, Ghayas C. Issa, Marina Konopleva, Michael Andreeff, Farhad Ravandi, Guillermo Garcia-Manero, Hussein A. Abbas
Journal: Clinical Cancer Research
Clin Cancer Res (2025)
https://doi.org/10.1158/1078-0432.CCR-25-0229
Published: 08 April 2025
View articletitled, Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis
Open the PDF for Azacitidine, Venetoclax and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase 1b/2 Study and Correlative Analysis in another window
Includes: Supplementary data
Journal Articles

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Jayastu Senapati, Warren C. Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia-Manero, Tapan Kadia, Courtney D. DiNardo, Elias Jabbour, Jan Burger, Nicholas J. Short, Yesid Alvarado, Nitin Jain, Lucia Masarova, Ghayas C. Issa, Wei Qiao, Joseph D. Khoury, Sherry Pierce, Darla Miller, Koji Sasaki, Marina Konopleva, Kapil N. Bhalla, Gautam Borthakur, Naveen Pemmaraju
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (21): 4352–4360.
https://doi.org/10.1158/1078-0432.CCR-23-1429
Published: 01 November 2023
View articletitled, Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Open the PDF for Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies in another window
Includes: Supplementary data
Journal Articles

A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML

David Levitz, Yogen Saunthararajah, Kateryna Fedorov, Lauren C. Shapiro, Ioannis Mantzaris, Aditi Shastri, Noah Kornblum, R. Alejandro Sica, Nishi Shah, Marina Konopleva, Kira Gritsman, Ira Braunschweig, Dennis L. Cooper, Kith Pradhan, Amit Verma, Eric J. Feldman, Mendel Goldfinger
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2774–2780.
https://doi.org/10.1158/1078-0432.CCR-23-0842
Published: 01 August 2023
View articletitled, A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
Open the PDF for A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML in another window
Includes: Supplementary data
Journal Articles

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Daniel A. Pollyea, Courtney D. DiNardo, Martha L. Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A. Rizzieri, B. Douglas Smith, Atsushi Shinagawa, Roberto M. Lemoli, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Hagop M. Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2753–2761.
https://doi.org/10.1158/1078-0432.CCR-21-3467
Published: 01 July 2022
View articletitled, Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Open the PDF for Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations in another window
Includes: Supplementary data
Journal Articles

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Jacqueline S. Garcia, Christian Recher, Vinod Pullarkat, Hagop M. Kantarjian, Courtney D. DiNardo, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Andrew H. Wei
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2744–2752.
https://doi.org/10.1158/1078-0432.CCR-21-3405
Published: 01 July 2022
View articletitled, Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
Open the PDF for Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia

Xuejie Jiang, Po Yee Mak, Hong Mu, Wenjing Tao, Duncan H. Mak, Steven Kornblau, Qi Zhang, Peter Ruvolo, Jared K. Burks, Weiguo Zhang, Teresa McQueen, Rongqing Pan, Hongsheng Zhou, Marina Konopleva, Jorge Cortes, Qifa Liu, Michael Andreeff, Bing Z. Carter
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (10): 2417–2429.
https://doi.org/10.1158/1078-0432.CCR-17-1556
Published: 14 May 2018
View articletitled, Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia
Open the PDF for Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)

Koichi Takahashi, Feng Wang, Kiyomi Morita, Keyur Patel, Carlos Bueso-Ramos, Abdallah Abou Zahr, Curtis Gumbs, Latasha Little, Samantha Tippen, Rebecca Thornton, Marcus Coyle, Jianhua Zhang, Xingzhi Song, Marisela Mendoza, Chang-Jiu Wu, Steven Kornblau, Courtney DiNardo, Guillermo Garcia-Manero, Elias Jabbour, Michael Andreeff, Farhad Ravandi, Hagop Kantarjian, Jorge Cortes, Marina Konopleva, Andrew Futreal
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24_Supplement): 16.
https://doi.org/10.1158/1557-3265.HEMMAL17-16
Published: 14 December 2017
View articletitled, Abstract 16: Genomic landscape of adult mixed phenotype acute leukemia (MPAL)
Journal Articles

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

Lina Han, Jeffrey L. Jorgensen, Chris Brooks, Ce Shi, Qi Zhang, Graciela M. Nogueras González, Antonio Cavazos, Rongqing Pan, Hong Mu, Sa A. Wang, Jin Zhou, Gheath AI-Atrash, Stefan O. Ciurea, Mike Rettig, John F. DiPersio, Jorge Cortes, Xuelin Huang, Hagop M. Kantarjian, Michael Andreeff, Farhad Ravandi, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3385–3395.
https://doi.org/10.1158/1078-0432.CCR-16-1904
Published: 02 July 2017
View articletitled, Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
Open the PDF for Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy

Natalia Baran, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2382–2390.
https://doi.org/10.1158/1078-0432.CCR-16-0895
Published: 14 May 2017
View articletitled, Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Open the PDF for Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy in another window
Journal Articles

Abstract PR01: IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities

Philip Jones, M Emilia Di Francesco, Jennifer M. Molina, Marina Protopopova, Madhavi Bandi, Jennifer Bardenhagen, Christopher A. Bristow, Christopher L. Carroll, Ningping Feng, Jason P. Gay, Mary K. Geck Do, Jennifer M. Greer, Marina Konopleva, Zhijun Kang, Gang Liu, Timothy McAfoos, Pietro Morlacchi, Melinda G. Smith, Sonal Fnu, Jay P. Theroff, Giulio Draetta, Giulio Draetta, Carlo Toniatti, Joseph R. Marszalek
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1_Supplement): PR01.
https://doi.org/10.1158/1557-3265.PMCCAVULN16-PR01
Published: 02 January 2017
View articletitled, Abstract PR01: IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities
Journal Articles

Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models

Juliana Benito, Marc S. Ramirez, Niki Zacharias Millward, Juliana Velez, Karine G. Harutyunyan, Hongbo Lu, Yue-xi Shi, Polina Matre, Rodrigo Jacamo, Helen Ma, Sergej Konoplev, Teresa McQueen, Andrei Volgin, Marina Protopopova, Hong Mu, Jaehyuk Lee, Pratip K. Bhattacharya, Joseph R. Marszalek, R. Eric Davis, James A. Bankson, Jorge E. Cortes, Charles P. Hart, Michael Andreeff, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1687–1698.
https://doi.org/10.1158/1078-0432.CCR-14-3378
Published: 31 March 2016
View articletitled, Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models
Open the PDF for Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models in another window
Includes: Supplementary data
Journal Articles

Abstract IA29: Using mitochondria to guide leukemia therapy.

Anthony Letai, Leah Hogdal, Triona Chonghaile, Alejandro Gutierrez, Justine Roderick, Michelle Kelliher, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): IA29.
https://doi.org/10.1158/1557-3265.HEMMAL14-IA29
Published: 19 August 2015
View articletitled, Abstract IA29: Using mitochondria to guide leukemia therapy.
Journal Articles

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, Yanis Boumber, Hagop Kantarjian, Farhad Ravandi, Jorge Cortes, Michael E. Rytting, Jitesh D. Kawedia, Jordan Basnett, Kirk S. Culotta, Zhihong Zeng, Hongbo Lu, Mary Ann Richie, Rebecca Garris, Lianchun Xiao, Wenbin Liu, Keith A. Baggerly, Elias Jabbour, Susan O'Brien, Jan Burger, Linda J. Bendall, Deborah Thomas, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-14-2888
Published: 14 June 2015
View articletitled, A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Open the PDF for A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies

Weiguo Zhang, Chen Gao, Marina Konopleva, Ye Chen, Rodrigo O. Jacamo, Gautam Borthakur, Jorge E. Cortes, Farhad Ravandi, Abhijit Ramachandran, Michael Andreeff
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2363–2374.
https://doi.org/10.1158/1078-0432.CCR-13-2052
Published: 30 April 2014
View articletitled, Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Open the PDF for Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies in another window
Includes: Supplementary data
Journal Articles

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer Wheler, Donald Lawrence, Joseph Paul Eder, Colin J. Meyer, Deborah A. Ferguson, James Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Kufe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3396–3406.
https://doi.org/10.1158/1078-0432.CCR-11-2703
Published: 14 June 2012
View articletitled, A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Open the PDF for A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma

Elias Drakos, Athanasios Thomaides, L. Jeffrey Medeiros, Jiang Li, Vasiliki Leventaki, Marina Konopleva, Michael Andreeff, George Z. Rassidakis
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3380–3387.
https://doi.org/10.1158/1078-0432.CCR-06-2581
Published: 01 June 2007
View articletitled, Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma
Open the PDF for Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma in another window
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View articletitled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells

Shishir Shishodia, Gautam Sethi, Marina Konopleva, Michael Andreeff, Bharat B. Aggarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1828–1838.
https://doi.org/10.1158/1078-0432.CCR-05-2044
Published: 21 March 2006
View articletitled, A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells
Open the PDF for A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells in another window
Journal Articles

Raf-1 and Bcl-2 Induce Distinct and Common Pathways That Contribute to Breast Cancer Drug Resistance

Julianne M. Davis, Patrick M. Navolanic, Caroline R. Weinstein-Oppenheimer, Linda S. Steelman, Wei Hu, Marina Konopleva, Mikhail V. Blagosklonny, James A. McCubrey
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (3): 1161–1170.
Published: 01 March 2003
View articletitled, Raf-1 and Bcl-2 Induce Distinct and Common Pathways That Contribute to Breast Cancer Drug Resistance
Open the PDF for Raf-1 and Bcl-2 Induce Distinct and Common Pathways That Contribute to Breast Cancer Drug Resistance in another window